Efficacy  	Efficacy  	 NNP	O
and  	and  	 CC	O
tolerability  	tolerability  	 NN	B-NP
of  	of  	 IN	O
a  	a  	 DT	O
cream  	cream  	 NN	O
containing  	containing  	 VBG	B-NP
AR-GG27®  	AR-GG27®  	 NNP	I-NP
( 	( 	 -LRB-	O
sorbityl  	sorbityl  	 FW	B-NP
furfural  	furfural  	 FW	I-NP
palmitate 	palmitate 	 FW	I-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
mild 	mild 	 JJ	B-NP
/ 	/ 	 CD	I-NP
moderate  	moderate  	 JJ	I-NP
childhood  	childhood  	 NN	I-NP
atopic  	atopic  	 NNS	I-NP
dermatitis  	dermatitis  	 VBP	I-NP
associated  	associated  	 VBN	O
with  	with  	 IN	O
pityriasis  	pityriasis  	 JJ	B-NP
alba 	alba 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
double-blind 	double-blind 	 JJ	B-NP
,  	,  	 ,	O
placebo-controlled  	placebo-controlled  	 JJ	O
clinical  	clinical  	 JJ	B-NP
trial  	trial  	 NN	I-NP
Pityriasis  	Pityriasis  	 FW	I-NP
alba  	alba  	 FW	I-NP
( 	( 	 -LRB-	O
PA 	PA 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
a  	a  	 DT	O
skin  	skin  	 NN	O
disorder  	disorder  	 NN	O
characterized  	characterized  	 VBN	O
by  	by  	 IN	O
finely  	finely  	 JJ	O
scaly 	scaly 	 NN	O
,  	,  	 ,	O
hypopigmented  	hypopigmented  	 JJ	B-NP
patches 	patches 	 NN	I-NP
,  	,  	 ,	O
typical  	typical  	 JJ	O
of  	of  	 IN	O
childhood 	childhood 	 NN	O
,  	,  	 ,	O
that  	that  	 WDT	O
also  	also  	 RB	O
represents  	represents  	 VBZ	O
an  	an  	 DT	O
atopic  	atopic  	 JJ	B-NP
dermatitis  	dermatitis  	 NNS	I-NP
( 	( 	 -LRB-	O
AD 	AD 	 NNP	B-NP
)  	)  	 -RRB-	O
minor  	minor  	 JJ	O
sign  	sign  	 NN	O
according  	according  	 VBG	O
to  	to  	 TO	O
Hanifin  	Hanifin  	 NNP	B-NP
and  	and  	 CC	O
Rajka  	Rajka  	 NNP	B-NP
criteria 	criteria 	 NNS	I-NP
.  	.  	 .	O
It  	It  	 PRP	O
may  	may  	 MD	O
be  	be  	 VB	O
isolated  	isolated  	 VBN	O
or  	or  	 CC	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
AD  	AD  	 NNP	O
representing 	representing 	 VBG	O
,  	,  	 ,	O
sometimes  	sometimes  	 RB	O
an  	an  	 DT	O
atypical  	atypical  	 JJ	O
manifestation  	manifestation  	 NN	B-NP
of  	of  	 IN	O
AD  	AD  	 NNP	O
during  	during  	 IN	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
follow-up  	follow-up  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
disease 	disease 	 NN	O
.  	.  	 .	O
Aim  	Aim  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
of  	of  	 IN	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
tolerability  	tolerability  	 NN	B-NP
of  	of  	 IN	I-NP
AR-GG27®  	AR-GG27®  	 NNP	I-NP
( 	( 	 -LRB-	O
sorbityl  	sorbityl  	 FW	B-NP
furfural  	furfural  	 FW	I-NP
palmitate 	palmitate 	 FW	I-NP
)  	)  	 -RRB-	O
cream  	cream  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
childhood  	childhood  	 JJ	O
mild  	mild  	 JJ	O
or  	or  	 CC	O
moderate  	moderate  	 JJ	O
AD  	AD  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
PA 	PA 	 NNP	O
.  	.  	 .	O
The  	The  	 DT	O
trial  	trial  	 NN	O
is  	is  	 VBZ	O
a  	a  	 DT	O
single  	single  	 JJ	O
center 	center 	 NN	O
,  	,  	 ,	O
double-blind 	double-blind 	 NNP	B-NP
,  	,  	 ,	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
placebo-controlled  	placebo-controlled  	 JJ	O
study 	study 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
study  	study  	 NN	O
included  	included  	 VBD	O
patients  	patients  	 NNS	O
of  	of  	 IN	O
both  	both  	 DT	O
sexes 	sexes 	 NN	O
,  	,  	 ,	O
aged  	aged  	 VBN	O
between  	between  	 IN	O
two  	two  	 CD	O
months  	months  	 NNS	O
and  	and  	 CC	O
15  	15  	 CD	O
years 	years 	 NNS	O
,  	,  	 ,	O
suffering  	suffering  	 VBG	O
from  	from  	 IN	O
mild  	mild  	 JJ	O
and  	and  	 CC	O
moderate  	moderate  	 JJ	O
AD  	AD  	 NNP	O
always  	always  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
PA 	PA 	 NNP	O
.  	.  	 .	O
Xerosis  	Xerosis  	 NNP	B-NP
was  	was  	 VBD	O
present  	present  	 JJ	O
in  	in  	 IN	O
all  	all  	 DT	O
patients 	patients 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
topical  	topical  	 JJ	B-NP
steroids  	steroids  	 NNS	I-NP
or  	or  	 CC	O
topical  	topical  	 FW	B-NP
calcineurin  	calcineurin  	 FW	I-NP
inhibitors  	inhibitors  	 FW	I-NP
( 	( 	 -LRB-	O
TIMs 	TIMs 	 NNP	B-NP
)  	)  	 -RRB-	O
had  	had  	 VBD	O
to  	to  	 TO	O
be  	be  	 VB	O
suspended  	suspended  	 VBN	O
for  	for  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
15  	15  	 CD	O
days 	days 	 NNS	O
.  	.  	 .	O
Any  	Any  	 DT	O
systemic  	systemic  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
and  	and  	 CC	O
phototherapy  	phototherapy  	 NNS	B-NP
or  	or  	 CC	O
sun  	sun  	 NN	O
exposure  	exposure  	 NN	O
were  	were  	 VBD	O
withdrawn  	withdrawn  	 VBN	O
at  	at  	 IN	O
least  	least  	 JJS	O
30  	30  	 CD	O
days  	days  	 NNS	O
before 	before 	 RB	O
.  	.  	 .	O
Emollients  	Emollients  	 NNP	B-NP
were  	were  	 VBD	O
stopped  	stopped  	 VBN	O
at  	at  	 IN	O
least  	least  	 JJS	O
seven  	seven  	 CD	O
days  	days  	 NNS	O
before 	before 	 RB	O
.  	.  	 .	O
During  	During  	 IN	O
the  	the  	 DT	O
trial 	trial 	 NN	O
,  	,  	 ,	O
no  	no  	 DT	O
other  	other  	 JJ	O
local  	local  	 JJ	O
or  	or  	 CC	O
systemic  	systemic  	 JJ	B-NP
treatments  	treatments  	 NNS	I-NP
were  	were  	 VBD	O
allowed 	allowed 	 VBN	O
,  	,  	 ,	O
as  	as  	 RB	O
well  	well  	 RB	O
as  	as  	 IN	O
sun  	sun  	 NN	O
exposure 	exposure 	 NN	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
affected  	affected  	 VBN	O
by  	by  	 IN	O
AD  	AD  	 NNP	O
with  	with  	 IN	O
viral 	viral 	 JJ	O
,  	,  	 ,	O
bacterial  	bacterial  	 JJ	O
or  	or  	 CC	O
fungal  	fungal  	 JJ	B-NP
overinfection  	overinfection  	 NN	I-NP
or  	or  	 CC	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
diabetes  	diabetes  	 JJ	B-NP
mellitus 	mellitus 	 NN	I-NP
,  	,  	 ,	O
severe  	severe  	 JJ	O
systemic  	systemic  	 JJ	B-NP
diseases  	diseases  	 NNS	I-NP
or  	or  	 CC	O
intolerance  	intolerance  	 JJ	O
to  	to  	 TO	O
one  	one  	 CD	O
or  	or  	 CC	O
more  	more  	 JJR	O
components  	components  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
product  	product  	 NN	O
were  	were  	 VBD	O
excluded 	excluded 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
primary  	primary  	 JJ	B-NP
endpoint  	endpoint  	 NN	I-NP
was  	was  	 VBD	O
the  	the  	 DT	O
evaluation  	evaluation  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
average  	average  	 JJ	O
change  	change  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
Investigator  	Investigator  	 NNP	B-NP
Global  	Global  	 NNP	I-NP
Assessment  	Assessment  	 NNP	I-NP
( 	( 	 -LRB-	O
IGA 	IGA 	 NNP	B-NP
)  	)  	 -RRB-	O
after  	after  	 IN	O
15  	15  	 CD	O
and  	and  	 CC	O
30  	30  	 CD	O
days  	days  	 NNS	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
second  	second  	 JJ	O
endpoint  	endpoint  	 NN	B-NP
was  	was  	 VBD	O
the  	the  	 DT	O
evaluation  	evaluation  	 NN	O
of  	of  	 IN	O
severity  	severity  	 NN	O
of  	of  	 IN	O
three  	three  	 CD	O
different  	different  	 JJ	O
clinical  	clinical  	 JJ	B-NP
signs 	signs 	 NNS	I-NP
:  	:  	 :	O
erythema 	erythema 	 CD	B-NP
,  	,  	 ,	O
excoriation  	excoriation  	 JJ	B-NP
desquamation 	desquamation 	 NN	I-NP
,  	,  	 ,	O
using  	using  	 VBG	O
a  	a  	 DT	O
subjective  	subjective  	 JJ	B-NP
five-point  	five-point  	 JJ	I-NP
scale 	scale 	 NN	I-NP
.  	.  	 .	O
Changes  	Changes  	 NNS	O
in  	in  	 IN	O
pruritus  	pruritus  	 JJ	B-NP
severity  	severity  	 NN	I-NP
was  	was  	 VBD	O
also  	also  	 RB	O
considered  	considered  	 VBN	O
during  	during  	 IN	O
the  	the  	 DT	O
entire  	entire  	 JJ	O
period  	period  	 NN	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
,  	,  	 ,	O
through  	through  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
Visual  	Visual  	 NNP	B-NP
Analogue  	Analogue  	 NNP	I-NP
Scale  	Scale  	 NNP	I-NP
( 	( 	 -LRB-	O
VAS 	VAS 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
P  	P  	 NN	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
,  	,  	 ,	O
two  	two  	 CD	O
tailed  	tailed  	 NNS	O
was  	was  	 VBD	O
considered  	considered  	 VBN	O
as  	as  	 IN	O
statistically  	statistically  	 JJ	O
significant 	significant 	 JJ	O
.  	.  	 .	O
After  	After  	 IN	O
15  	15  	 CD	O
and  	and  	 CC	O
30  	30  	 CD	O
days  	days  	 NNS	O
there  	there  	 EX	O
was  	was  	 VBD	O
a  	a  	 DT	O
statistically  	statistically  	 JJ	O
significant  	significant  	 JJ	O
difference  	difference  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
group  	group  	 NN	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
AR-GG27® 	AR-GG27® 	 NNP	B-NP
,  	,  	 ,	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
placebo  	placebo  	 NN	O
( 	( 	 -LRB-	O
respectively 	respectively 	 RB	O
,  	,  	 ,	O
P=0.0007  	P=0.0007  	 NNP	O
and  	and  	 CC	O
P=0.005 	P=0.005 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
After  	After  	 IN	O
15  	15  	 CD	O
days  	days  	 NNS	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
,  	,  	 ,	O
itching  	itching  	 NN	O
was  	was  	 VBD	O
clearly  	clearly  	 RB	O
reduced  	reduced  	 VBN	O
in  	in  	 IN	O
AR-GG27®  	AR-GG27®  	 CD	B-NP
treated  	treated  	 JJ	O
group  	group  	 NN	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
placebo 	placebo 	 NN	O
,  	,  	 ,	O
both  	both  	 DT	O
in  	in  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	B-NP
population  	population  	 NN	I-NP
( 	( 	 -LRB-	O
P=0.01 	P=0.01 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
where  	where  	 WRB	O
the  	the  	 DT	O
symptom  	symptom  	 NN	B-NP
was  	was  	 VBD	O
present  	present  	 JJ	O
from  	from  	 IN	O
the  	the  	 DT	O
beginning  	beginning  	 NN	O
( 	( 	 -LRB-	O
P=0.05 	P=0.05 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
AR-GG27®  	AR-GG27®  	 NNP	B-NP
showed  	showed  	 VBD	O
a  	a  	 DT	O
beneficial  	beneficial  	 JJ	O
action  	action  	 NN	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
high  	high  	 JJ	O
compliance  	compliance  	 NN	O
and  	and  	 CC	O
tolerability  	tolerability  	 NN	B-NP
in  	in  	 IN	O
dermatological  	dermatological  	 JJ	B-NP
skin  	skin  	 NN	I-NP
conditions  	conditions  	 NNS	I-NP
characterized  	characterized  	 VBN	O
by  	by  	 IN	O
inflammation  	inflammation  	 NN	B-NP
and  	and  	 CC	O
tissue  	tissue  	 NN	B-NP
oxidative  	oxidative  	 NN	I-NP
stress  	stress  	 NN	I-NP
in  	in  	 IN	O
children 	children 	 NNS	O
,  	,  	 ,	O
as  	as  	 IN	O
PA  	PA  	 NNP	O
with  	with  	 IN	O
mild  	mild  	 JJ	O
and  	and  	 CC	O
moderate  	moderate  	 JJ	O
AD 	AD 	 NNP	O
.  	.  	 .	O
